Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins. - Test2 - elhamkhani - TriplyDB

Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins.

Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins.

http://www.wikidata.org/entity/Q37569365

about

Fragile X spectrum disorders Fragile X-associated tremor/ataxia syndrome.Unstable mutations in the FMR1 gene and the phenotypes Does diisocyanate exposure result in neurotoxicity?Phenobarbital use and neurological problems in FMR1 premutation carriers Using mouse models of autism spectrum disorders to study the neurotoxicology of gene-environment interactions Towards an Understanding of Neuropsychiatric Manifestations in Fragile X Premutation Carriers Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder.Sleep apnea in fragile X premutation carriers with and without FXTAS.Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers Mouse models of the fragile x premutation and the fragile X associated tremor/ataxia syndrome.Psychosis and catatonia in fragile X: Case report and literature review.Cascade Screening for Fragile X Syndrome/CGG Repeat Expansions in Children Attending Special Education in Sri Lanka.Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.Neurocognitive endophenotypes in CGG KI and Fmr1 KO mouse models of Fragile X-Associated disorders: an analysis of the state of the field Aging in Fragile X Premutation Carriers.Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) Motor Dysfunction Modeled in Mice Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.Fragile X-associated tremor/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene.Women who carry a fragile X premutation are biologically older than noncarriers as measured by telomere length.Newborn screening and cascade testing for FMR1 mutations.

P2860

Q26824376-60F6ACFF-80FB-44D3-98D7-9805DFEA0C2C Q26852667-D32F5B2D-5CC7-4C97-AC28-80028C087046 Q26996649-C381923F-D9E2-413B-9C45-167551D7A139 Q27006543-4351325C-2C30-4E3A-BDBC-68D712BCDE65 Q28390629-288F062D-F59C-4073-8417-9CAD8F3EE47F Q28392778-0AF8B55F-A656-4BE3-84EC-F300BA112065 Q33863331-A9244755-93F4-4811-9AFA-89E3886A80DB Q33926696-062992D5-E519-4C6B-BD22-A53E8B0738AE Q33943666-A135F63E-2178-41C4-8BEA-A3BE3E07EADD Q34198650-8A96BD96-98A4-4989-A615-C2334CDE0167 Q34575595-91800770-09CD-47DB-B413-B89CB9005788 Q35037764-6A05A131-7146-4AB1-B1DF-00F5A55E8F0E Q35771116-0173E221-D54A-486A-9CE4-F9CE1B31C3A9 Q35875408-4632EC05-A982-4E6A-A3DA-0E1DB3EE9AA0 Q36188438-C48F7D7E-8E10-4B0C-B6F6-F5C0AA29223F Q36399716-A0072E65-2C7C-42BC-A925-48078FA5A8EF Q37580522-F0C2389B-F146-4812-8597-F38D8E871242 Q37623407-8B20D29B-6CC8-44A1-919E-345CAC30A663 Q38849578-F4ABFC62-DF1E-468C-94D3-4F0116BC70F9 Q38851924-94A2CE1C-81B7-4402-8341-DFBD654B7521 Q38859181-68644946-060F-4E3D-B895-277EAB2C79A9 Q50264940-7F443395-103A-4B97-B409-E120185C60DD Q53799975-239F773E-C3E2-46AC-8079-CA5CACD68E9E Q55501801-76AF18EA-B5AB-4B67-91F7-A1F795530603

P2860

Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins.

http://www.wikidata.org/entity/Q37569365

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Early onset of neurological sy ...... rriers exposed to neurotoxins.

@en

Early onset of neurological sy ...... rriers exposed to neurotoxins.

@nl

type

label

Early onset of neurological sy ...... rriers exposed to neurotoxins.

@en

Early onset of neurological sy ...... rriers exposed to neurotoxins.

@nl

prefLabel

Early onset of neurological sy ...... rriers exposed to neurotoxins.

@en

Early onset of neurological sy ...... rriers exposed to neurotoxins.

@nl

P1433

Q37569365-5E3EE730-B560-4D03-B514-AFBA2A52EFC0

P1476

Q37569365-973922E8-EB50-44BE-BB58-9EE799AABB93

P2093

Q37569365-0442DF56-C6CD-4DC3-B5DF-54F97CFF950C

Q37569365-12862E8F-EDC5-4DE0-94F3-62085911358A

Q37569365-2120B09A-5F3B-4512-BDD5-74ED21786DC4

Q37569365-31689AA8-9F40-46C7-ADCB-60586A4AB37B

Q37569365-447116B8-02C0-412E-A24C-A9CC7B05CA0C

Q37569365-4F7B1BDA-892C-4721-9D0C-DA94299AC56D

Q37569365-528A7572-B7E2-430C-937B-DAC0777DC147

Q37569365-794E09EB-134E-49D5-8085-F86624AB0DCC

Q37569365-8F8DB5EE-CDA6-429D-AAE6-3D4CA32083B6

Q37569365-BD45E793-CEF9-40BE-A215-ACCC285C0290

P2860

Q37569365-0952B302-53B6-4607-8CC6-4D9DFB2C3C77

Q37569365-0BB8702B-A42A-42B8-8FAF-3F204B33EE88

Q37569365-103A16D7-CD8C-4132-AA44-2E3324BC4A7B

Q37569365-1262B5DF-C108-440B-832F-B102FA617916

Q37569365-3757B61D-7A9D-426C-BB0C-88016062EEF4

Q37569365-3D16673B-3E68-4A64-ABF6-64559AE5136C

Q37569365-47686DB3-1C2A-4673-9CFF-1EDAE04991FB

Q37569365-4CB3A973-8F54-4DC7-ACF3-19683E6AAD1B

Q37569365-53590496-7CCB-4BF7-9E07-83C4A7D7D386

Q37569365-53CD4373-1E3D-428D-BE80-B9C8927DD73B

P304

Q37569365-FBBEACA8-AAA7-45E7-B380-8E4FD58A6433

P31

Q37569365-594DCBEA-B98F-41EF-8660-681D07D82E5B

P356

Q37569365-606E8A20-5CE1-4EB6-A637-8D58AB05CC37

P433

Q37569365-B1759369-F33D-4F86-BD92-67058BCA9291

P478

Q37569365-6DC54506-8092-451D-BC1E-A9701803E473

P577

Q37569365-5193AF04-1A55-4728-8C2A-089FBCEAF9F0

P5875

Q37569365-D76926CF-028E-4CBC-8FAC-4912682CCA5D

P698

Q37569365-F98F34F4-AB37-42FB-8D07-E81B706D4AB3

P932

Q37569365-DA7AA43B-5035-4CAC-85D3-18589426C13D

P356

J.NEURO.2010.04.002

P1433

NeuroToxicology

P1476

Early onset of neurological sy ...... rriers exposed to neurotoxins.

@en

P2093

Danh V Nguyen

http://www.w3.org/2001/XMLSchema#string

Flora Tassone

http://www.w3.org/2001/XMLSchema#string

Isaac N Pessah

http://www.w3.org/2001/XMLSchema#string

James A Bourgeois

http://www.w3.org/2001/XMLSchema#string

James A Brunberg

http://www.w3.org/2001/XMLSchema#string

Louise Gane

http://www.w3.org/2001/XMLSchema#string

Michele Ono

http://www.w3.org/2001/XMLSchema#string

Patrick E Adams

http://www.w3.org/2001/XMLSchema#string

Paul J Hagerman

http://www.w3.org/2001/XMLSchema#string

Randi Hagerman

http://www.w3.org/2001/XMLSchema#string

P2860

Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome

Occupational exposure to hexachlorocyclopentadiene. How safe is sewage?

A review of fragile X premutation disorders: expanding the psychiatric perspective

Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers

Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis

Respiratory effects of toluene diisocyanate in the workplace: a discussion of exposure-response relationships.

Environmental fate and bioavailability of Agent Orange and its associated dioxin during the Vietnam War.

The fragile X prevalence paradox

Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration.

Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the expression of synaptic proteins in dissociated rat cortical cells.

P304

399-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEURO.2010.04.002

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44595498

http://www.w3.org/2001/XMLSchema#string

P698

20466021

http://www.w3.org/2001/XMLSchema#string

P932

3918243

http://www.w3.org/2001/XMLSchema#string